



“The Health Innovator”  
as Korea’s leading global total healthcare company.



# HANDOK. Inc.

www.handok.co.kr/eng

Handok has a core business focus in diabetes, cardiovascular, muscular skeletal, psychoneurotic disease, human vaccines, medical devices, diagnostics and consumer health. Handok, founded in 1954, grew as a joint venture with Hoechst/Aventis/Sanofi from 1964 to 2012. Handok has also established strategic collaborations in several areas with multiple multinational pharmaceutical companies. For more information, please visit [www.handok.co.kr](http://www.handok.co.kr).

## Main Products

	Product	Indication	Main Export
Endocrine system	Amaryl M, Amaryl MEX	Glimepiride Metformin	Thailand, Dubai, Russia, Hungary, UAE, Philippines, Singapore etc.
	Tenelia M	Teneligliptin, Metformin	-
	Daonil tab.	Glibenclamide	
Integumentary system	Esperson oint. 0.25%	Desoxymethasone Semi-solid	Thailand, Taiwan
Central nervous system	Frisium tab. 10mg	Clobazam	
Cardiovascular system	Lasix tab.	Furosemide	Thailand, Taiwan, Philippines
Osteoarthritis and muscular pain	KETOTOP Plaster	Ketoprofen	Myanmar, Vietnam, Singapore, Kazakhstan, Malaysia etc.

CEO  
Young Jin Kim, Jin Ki Baik

Location  
132, Teheran-ro, Gangnam-gu, Seoul, 06235, Korea

Specialty  
1. Anti-diabetics New Chemical Entities  
2. Anti-diabetics Diabetes Incrementally Modified Drugs  
3. Anti-arthritis Plaster

Tel / Fax / E-mail  
T. 82-2-527-5114  
F. 82-2-527-5001  
E. Handok@handok.com

## R&D Pipeline

Therapeutic Area	Project	Classification	Indication	Dis.	Pre clinical	Phase I	Phase II	Phase III	Remarks
Orphan	HL2356 (GX-H9)	Biologics	Adult Growth Hormone Deficiency				■		• Genexine Partnered • Supported by Government Funding (KDDF**)
			Pediatric Growth Hormone Deficiency				■		
Oncology	HL5101	Chemical	Cancer		■				• CMG Pharm. Partnered • Supported by NOV***
Ophthalmology	HL3501	Chemical	Glaucoma	■					• Supported by Government Funding (KDDF**)
Diabetes/ Metabolism	HD-P550	IMD*	Diabetes + Hyperlipidemia		■				
	HD-C715	Chemical	Diabetes	■					
Cardio Vascular	DENEX	Resistant Hypertension	Medical Device				■		• CE Mark approved (2016yr)
CVD/Infectious Disease	Nanocon RST kit	Medical Device_IVD (IVD: in-vitro Diagnostic)	CVD/Infectious Disease				■		

\*IMD: Incrementally Modified Drug

\*\*KDDF: Korea Drug Development Fund

\*\*\*NOV: National OncoVenture

■ Biologics ■ Small Molecule ■ Medical Device